GEN-MKT-18-7897-A
Oct 25, 2016 | Blogs, Technology | 0 comments
The M3 MicroLC System is designed for scientists who are struggling to analyze small volume samples with conventional LC-MS and need to lower their limits of quantitation while maintaining throughput and robustness.
When designing the M3 MicroLC System, we focused on creating an easy-to-use LC that would make microflow LC simple – even for those new to the technique.
With the M3 MicroLC System you can:
We are also pleased to announce that the MicroLC System is the recipient of the 2016 Instrument Business Outlook’s (IBO) Silver Analytical Instrument Industrial Design Award. Each year Instrument Business Outlook (IBO) announces their awards for excellence in the industrial design of analytical instruments, portable analytical instruments, and laboratory equipment. The winners of the 2016 Awards demonstrate how industrial design can improve a product’s functionality and the end user’s experience. Criteria include innovation, aesthetics, functionality and utility. Award candidates are chosen from the new products that IBO monitors through trade shows, trade publications, press releases and the Internet. Read more about this award >
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network